Drug intelligence / Profile preview

REV-205

Development stage: Unknown
Lead developer: reV
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

REV-205 is a clinical-stage bispecific monoclonal antibody currently in Phase 2b development for the treatment of conditions in immunology and oncology. It was a key asset in the 2026 acquisition of the biotech firm REV by a larger pharmaceutical manufacturer. As a bispecific antibody, REV-205 is designed to simultaneously bind to two different targets, potentially offering superior efficacy or a novel mechanism of action compared to standard monoclonal antibodies.

Beyond the preview

Go deeper on REV-205.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REV-205.

Explore the full profile